Japan’s Daiichi Sankyo is looking at a reduced review time for its acute myeloid leukaemia (AML) drug quizartinib in Europe, the top prospect in its new oncology pipeline. The European Medicines ...
AstraZeneca and Daiichi Sankyo confirmed today that they have ... It's not clear yet if they will adopt the same go-to-market strategy in Europe. Preliminary results from TROPION-Lung05 reported ...
Hosted on MSN3mon
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLCBesides lung cancer, AstraZeneca and Daiichi Sankyo are also seeking approval of Dato-DXd for unresectable or metastatic HR+ HER2- breast cancer. A BLA for this breast cancer indication is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback